The pharmacokinetics of hexamethylmelamine (HMM) and its first metabolite (hydroxymethylpentamethylmelamine: HMPMM) following IP bolus dose of 200 mg/kg were studied in mice. The drug concentrations were determined by a sensitive reversed-phase HPLC assay. Thus, for the first time, HMM major hydroxy
Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors
β Scribed by J. Dubois; G. Atassi; M. Hanocq; F. Abikhalil
- Publisher
- Springer
- Year
- 1988
- Tongue
- English
- Weight
- 593 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
β¦ Synopsis
The pharmacokinetics of hexamethylmelamine (HMM) and its main metabolites hydroxymethylpentamethylmelamine (HMPMM), pentamethylmelamine (PMM), and 2,2,4,6, tetramethylmelamine (2,2,4,6 TetrMM) were studied in renal cell (RC) tumor tissues and plasma of CDF1 mice that had received IP bolus injections of the maximally tolerated dose (200 mg/kg) of HMM. HMM, PMM, and 2,2,4,6 TetrMM concentrations determined in RC tissues were much higher than the plasma values, as indicated by the pharmacokinetic parameters (Cmax and AUC). On the other hand, very low levels of HMPMM, generally considered to be a potentially active antitumor compound, were detected in the target tissues, whereas this hydroxylated metabolite was stable and easily determined in plasma. High HMM concentrations in RC tissues could correlate with the high sensitivity of the tumor to this drug. However, the behavior of HMPMM remains unclear; related hypotheses are presented in this paper.
π SIMILAR VOLUMES
The covalent binding of hexamethylmelamine (HMM) and its metabolites was studied in liver, tumor, blood, kidney, spleen, lung, brain, heart, and small intestine after a single IP injection of 2,4,6-14C-hexamethylmelamine (50 mg/kg) to C57Bl/6J female mice bearing 20-day-old M5076/73A ovarian cancer.
Fibrosarcoma-SA-I -tumor-bearing mice were treated S.C. in the vicinity of tumors (peri-tumorally) or intravenously, with recombinant human TNF-a lacking I to 3 amino acids from N-terminal part (TNF-aNv3). Tumor growth delay, observed after both routes of TNF-aNv3 application, was statistically sign
The effect of the combined administration of verapamil (i.p. twice daily) and doxorubicin (i.v. once weekly) was tested in mice bearing the following: (a) a tumor with induced resistance to doxorubicin (B16VDXR melanoma line); (b) a tumor inherently resistant (MXT mammary carcinoma); and (c) four so